Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
暂无分享，去创建一个
A. Salihoglu | B. Ferhanoğlu | L. Kaynar | Z. Başlar | S. Paydaş | V. Ozkocaman | P. Topçuoğlu | M. Ozcan | N. Karadurmuş | I. Karadoğan | E. Ozdemir | H. Goker | Z. Yeğin | T. Elverdi | G. Sucak | G. Erdem | G. Akyol | Z. Yeğin | E. Birtaş | A. Salihoğlu | S. Paydas | Elif Birtaş | Mustafa Özcan
[1] A. Santoro,et al. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials , 2013, Haematologica.
[2] J. Radford,et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center , 2013, Haematologica.
[3] B. Pro,et al. Heads or tails? Choosing a salvage therapy for relapsed/refractory Hodgkin lymphoma , 2013, Expert review of hematology.
[4] U. Jäger,et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. , 2012, Blood.
[5] A. Nademanee,et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. , 2012, Blood.
[6] Scott E. Smith,et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Gualberto. Brentuximab Vedotin (SGN-35), an antibody–drug conjugate for the treatment of CD30-positive malignancies , 2012, Expert opinion on investigational drugs.
[8] Z. Berneman,et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP , 2008, Annals of Hematology.
[9] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Drzezga,et al. Fluorodeoxyglucose positron emission tomography / computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma , 2014 .